Has Goetz Kloecker, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,178,151 in general payments to Goetz Kloecker, MD across 1,008 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Goetz Kloecker, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Goetz Kloecker, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Goetz Kloecker, MD

Hematology & Oncology · Louisville, KYNPI 1306827126

Payments from drug & device makers

$1,178,151in general payments, 2019–2025

Across 1,008 payments — averaging $1168.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$370K
E.r. Squibb & Sons, L.L.C.$155K
AstraZeneca$137K
Amgen$76K
Mirati Therapeutics, Inc.$68K
Regeneron Healthcare Solutions, Inc.$60K
plus $311K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	102	$369,977
E.r. Squibb & Sons, L.L.C.	97	$155,387
AstraZeneca(2 entities)	106	$136,909
Amgen	58	$76,376
Mirati Therapeutics, Inc.	27	$68,347
Regeneron Healthcare Solutions, Inc.	84	$60,378
Novocure Inc.	14	$53,833
Genentech USA, Inc.	48	$47,135
Jazz Pharmaceuticals Inc.	42	$46,581
Lilly USA, LLC	39	$32,791
Genentech, Inc.	1	$29,800
Sanofi	38	$22,715
EMD Serono, Inc.	14	$19,373
Novartis	68	$12,397
Dova Pharmaceuticals	2	$9,330
Daiichi Sankyo Inc.	51	$7,868
AbbVie	11	$5,805
Bayer	13	$5,464
Bristol Myers Squibb(2 entities)	12	$2,807
Eli Lilly	2	$2,150
Regeneron	2	$2,083
Gilead(2 entities)	9	$1,968
Eisai Inc.	3	$1,904
Puma Biotechnology, Inc.	7	$1,219
Pfizer	21	$913
Johnson & Johnson	16	$633
Incyte Corporation	20	$499
Coherus Oncology, Inc.	6	$451
Recordati_rare_diseases_inc.	5	$305
Boehringer Ingelheim	8	$260
Adaptive Biotechnologies Corporation	5	$247
Beigene USA, Inc.	5	$236
Foundation Medicine, Inc.	5	$197
Iovance Biotherapeutics, Inc.	1	$196
GSK	4	$178
Ipsen Biopharmaceuticals, Inc	2	$141
Stemline Therapeutics Inc.	6	$128
Exelixis Inc.	1	$120
Pharmacyclics LLC, An Abbvie Company	4	$92
Rigel Pharmaceuticals, Inc.	4	$84
Array Biopharma Inc	6	$83
Seagen Inc.	4	$72
Takeda Pharmaceuticals U.S.A., Inc.	3	$66
Pharmacosmos Therapeutics Inc.	3	$65
Sobi, Inc	3	$62
ADC Therapeutics America, Inc.	3	$58
Pharmaessentia USA Corporation	2	$54
AVEO Pharmaceuticals, Inc.	3	$49
Astellas Pharma US Inc	2	$47
Legend Biotech USA Inc.	2	$39
Geron Corporation	1	$35
Apellis Pharmaceuticals, Inc.	2	$34
Alnylam Pharmaceuticals Inc.	1	$26
Verastem, Inc.	1	$24
Nuvation Bio Inc.	1	$24
Agios Pharmaceuticals, Inc.	1	$22
Azurity Pharmaceuticals, Inc.	1	$19
CTI Biopharma Corp.	1	$19
G1 Therapeutics, Inc.	1	$18
Novo Nordisk	1	$16

How this compares

$1,178,151 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$39,572

Medicare patients

133

Services billed

380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Louisville

Joseph MalyLouisville$7M
Laila AgrawalLouisville$6.3M
Jaspreet GrewalLouisville$4.2M
Rebecca RedmanLouisville$2.1M
Vivek SharmaLouisville$1.9M
Rohit KumarLouisville$1.6M
Jeffrey HargisLouisville$1.3M
Elizabeth RileyLouisville$746K
Adam LyeLouisville$706K
Brian DongLouisville$664K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →